CRS-Group > references 

Reference List

  1. Dingemanse J, Halabi A, van Giersbergen PL. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan. J Clin Pharmacol 2009; 49(4):455-464.

  2. Feuring M, Ruf A, Schultz A, Wehling M. Blood group-dependent inhibition of platelet function by eptifibatide and abciximab. Submitted 2009.

  3. Feuring M, Wehling M, Schultz A. Circadian variation of platelet function measured with the PFA-100®. Platelets in press 2009.

  4. Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23(1):43-51.

  5. Tebbe U, Bramlage P, Graf A, Lechleitner P, Bode C, Riess FC, Clemens N, Al-Rawi Y, Konstantinides S, Goldhaber SZ. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost. 2009 Mar; 101(3):557-62.

  6. Baumann S. Sublingual immunotherapy (SLIT) adjuvanted with monophosphoryl lipid A (MPL®): preliminary safety, efficacy and immunogenicity results. The journal of allergy and clinical immunology, 2008 Oct. 08-1059.

  7. Fauteck JD, Ackermann G, Birkel M, Breuer M, Moor AC, Ebeling A, Ortland C. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses. Arch Dermatol Res. 2008 Feb; 300(2):53-60. Epub 2007 Oct 25.

  8. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134(2):255-262.

  9. Stass H, Kubitza D, Aydeniz B, Wallwiener D, Halabi A, Gleiter C. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102(2):132-136.

  10. Timmer W. Anforderungen an Einrichtungen zur Durchführung von Erstanwendungen (Demands on clinical units dedicated to the conduct of first-to-human trials). Lecture at the 10th Annual Congress of Clinical Pharmacology (VkliPha 2008), November 6-8, 2008, Berlin.

  11. Timmer W. Cardiac Safety – Dr Wolfgang Timmer of CRS examines the conduct of thorough QTc trials in practice from a Phase I CRO's perspective. European Pharmaceutical Contractor 2008; (Summer 08).

  12. Timmer W. Minimising risk by optimising clinical trial design and performance. Lecture and workshop at the annual meeting of the Arbeitsgemeinschaft für angewandte Humanpharmakologie [Association for Applied Human Pharmacology] (AGAH e.V.), April 17-19, 2008, Weimar.

  13. Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G, Scheuch G. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007 Oct; 47(10):1335-41. Epub 2007 Jul 11.

  14. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007; 9(4):R52.

  15. Pfaar O, Fischer von Weikersthal-Drachenberg KJ, Amersdorffer J, Baumann-Noss S, Woroniecki SR, Klimek L. Sublingual immunotherapy adjuvanted with monophosphoryl lipid A: preliminary efficacy and immunogenicity results. Allergy 2007; s83.

  16. Roell A, Schueller P, Schultz A, Losel R, Wehling M, Christ M, Feuring M. Effect of oral contraceptives and ovarian cycle on platelet function. Platelets 2007; 18(2):165-70.

  17. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf) 2007; 66(4):579-585.

  18. Bestehorn K, Honig R, Clemens N, Kirch W. Registries for clinical trials -- a critical stock-taking. Med Klin (Munich) 2006; 101(2):120-126.

  19. Bestehorn K, Clemens N. Addition to letters: an answer to the letter from Herrn Antes in ZaeFQ 99 (2005) 10, 663. Z Arztl Fortbild Qualitatssich 2006; 100(2):138.

  20. Jakobs R, Hartmann D, Kudis V, Eickhoff A, Schilling D, Weickert U, Siegler KE, Riemann JF. Risk factors for symptomatic stone recurrence after transpapillary laser lithotripsy for difficult bile duct stones using a laser with a stone recognition system. Eur J Gastroenterol Hepatol. 2006 May; 18(5):469-73.

  21. Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli WE. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006; 80(2):126-135.

  22. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krähenbühl S, Chadha-Boreham H, Dingemanse J. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther. 2006 Sep; 80(3):246-56.

  23. Timmer W. Klinische Arzneimittelentwicklung in der Industrie für Kinder unter Berücksichtigung von ICH-E11 [Clinical development of new drugs by the pharmaceutical industry in consideration of ICH-E11]. Lecture at the pediatric training course of the Koordinierungszentrum für Klinische Studien (KKS), May 30, 2006, University of Mainz.

  24. van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006; 44(3):113-118.

  25. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2006 Mar 15; 24(12):2065-70. Epub 2005 Nov 28.

  26. Wehling M, Schultz A, Losel R. Nongenomic actions of estrogens: Exciting opportunities for pharmacology. Maturitas 2006; 54: 321-26.

  27. Wehling M, Schultz A, Lösel R. To be or not to be (a receptor). Steroids 2006; 72(2):107-10.

  28. Brockmoller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 2005; 77(6):529-541.

  29. Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet 2005; 44(4):429-438.

  30. Dogterom P, van den Heuvel MM, Thomsen T. The Combined Contraceptive Ring Shows No Interaction with Oral Amoxicillin or Doxycycline in Two Randomised Trials. Clinical Pharmacokinetics 2005; In Press.

  31. Feuring M, Harenberg J, Peiter A, Ganschow A, Ruf A, Losel R, Wehling M, Schultz A. Impact of ABO blood groups on tirofiban mediated inhibition of platelet function. Platelets 2005; 16:430-4.

  32. Feuring M, Schultz A, Losel R, Wehling M. Monitoring Acetylsalicylic Acid Effects with the Platelet Function Analyzer PFA-100. Semin Thromb Hemost 2005; 31:411-5.

  33. Grossmann M, Baumann-Noss S, Voisin D, Parisi S. Evaluation of pharmacokinetic (PK) interaction between palonosetron (PALO) and dexamethason (DEX): A randomized, crossover study in healthy subjects. ECCO 2005. Abstract.

  34. Pietruck F, Kiel G, Birkel M, Stahlheber-Dilg B, Philipp T. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Biopharm Drug Dispos 2005; 26(4):135-141.

  35. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005 Jul; 78(1):25-33. Comment in: Clin Pharmacol Ther. 2005 Jul; 78(1):19-24.

  36. Schmidt BM, Horisberger K, Feuring M, Schultz A, Wehling M. Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism. Exp Clin Endocrinol Diabetes 2005; 113: 252-6.

  37. Schultz A. Therapeutischer Fortschritt beim akuten Koronarsyndrom durch Statine? Perfusion 2005; 18: 285-7.

  38. Senges-Becker JC, Klostermann M, Becker R, Bauer A, Siegler KE, Katus HA, Schoels W. What is the "optimal" follow-up schedule for ICD patients? Europace. 2005 Jul; 7(4):319-26.

  39. Stahlberg HJ, Beier H, Baumann-Noss S, Birkel M. Bioequivalence of a new clarithromycin 250 mg dst (dose sipping technology) granule formulation (clarosip®) compared to an equimolar reference suspension formulation (zeclar®). Abstract. 2005.

  40. Agrawal NG, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, Gottesdiener KM. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol 2004; 44: 1125-31.

  41. Bagchus WM, Houwing NS, Schnabel P, Lass H, Thomsen T. Effect of meal composition on serum testosterone level after oral administration Andriol® Testocaps®. Prague - Czech Republic: The 4th world congress on the aging male; February 26-29, 2004.

  42. Burkhardt U, Zahn R, Hoffler U, Siegler KE, Frilling B, Weber M, Gottwik M, Wehr M, Seidel F, Rosocha S, Tebbe U, Senges J. Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial. Z Kardiol. 2004 Sep; 93(9):671-8.

  43. Dingemanse J, Halabi A, Hoever P, Chadha-Boreham H, van Giersbergen PL. Clinical pharmacology of tezosentan, a dual endothelin receptor antagonist, in patients with liver cirrhosis. 105th Am.Soc. Clin. Pharmacol. Ther. Meeting, Miami Beach, FL, 2204, March 24-27. Clin Pharmacol Ther 2004; 75: P31.

  44. Dogterom P, Heuvel van den MM, Thomsen T, Verhoeven C. NuvaRing does not interact with oral antibiotics. Edinburgh - Scottland: 8th Congress of the European Society of Contraception; 2004.

  45. Dogterom P, van den Heuvel MM, Thomsen T. The contraceptive vaginal ring, NuvaRing®, shows no interaction with oral antibiotics. 04 Mar 24; Miami - Florida: ASCPT 2004 Annual Meeting, March 24-27, 2004.

  46. Doser S, Marz W, Reinecke MF, Ringleb P, Schultz A, Schwandt P, Becker HJ, Bonner G, Buerke M, Diener HC, Gohlke H, Keil U, Ringelstein EB, Steinmetz A, Gladisch R, Wehling M [Recommendations for statin therapy in the elderly]. Internist (Berl) 2004; 45: 1053-62.

  47. Grossmann M, Ebert U, Baumann- Noss S, Birkel M, Renner J, Luecker PW. An approach to characterize pharmacokinetic – pharmacodynamic bioequivalence of propofol. ASCPT 2004, Annual Meeting. Abstract.

  48. Junge W, Wilke B, Halabi A, Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 2004; 344(1-2):137-148.

  49. Losel R, Schultz A, Boldyreff B, Wehling M. Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 2004; 69:575-8.

  50. Losel R, Schultz A, Wehling M. A quick glance at rapid aldosterone action. Mol Cell Endocrinol 2004; 217: 137-41.

  51. Schöwel V, Drzewinska M, Burhenne J, Riedel KD, Thomsen T, Weiss J, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype releated, potent interaction between voriconazole and ritonavir. Stuttgart - Deutschland: 6. Jahreskongress für Klinische Pharmakologie; 2004.

  52. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Küstermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Brüning JC. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A. 2004 Mar 2; 101(9):3100-5. Epub 2004 Feb 23.

  53. Schürmann W, Barczok M, Timmer W, Pfaff HP, Hodder R. Preference for novel soft mist inhaler over pMDI in patients with COPD Poster, 14th ERS Annual Congress, Glasgow, UK, Sept 4-8, 2004, Abstract: Eur Resp J 2004, 24: P649.

  54. Subar M, Goss PE, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. Journal of Clinical Oncology; 2004.

  55. Tillmann HC, Stuck BA, Feuring M, Rossol-Haseroth K, Tran BM, Losel R, Schmidt BM, Hormann K, Wehling M, Schultz A. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest 2004; 34: 67-73.

  56. Tran-Mi B, Storch H, Seidel K, Schulzki T, Haubelt H, Anders C, Nagel D, Siegler KE, Vogt A, Seiler D, Hellstern P. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang. 2004 Apr; 86(3):189-97.

  57. Zeymer U, Zahn R, Siegler KE, Senges J. Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry. Herz. 2004 Nov; 29(7):651-5. German.

  58. Molter GP, Soltész S, Larsen R, Baumann-Noss S, Biedler A, Silomon M. Haemodynamic effects following preoperative hypervolemic haemodilution with hypertonic hyperoncotic colloid solutions in coronary artery bypass graft surgery. Anaesthesist. 2003 Oct; 52(10):905-18.

  59. Bier-Ulrich AM, Haubelt H, Anders C, Nagel D, Schneider S, Siegler KE, Seiler D, Hellstern P. The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo-controlled double-blind study. Transfusion. 2003 Mar; 43(3):405-10.

  60. Eckl KM, Sydorchuk L, Biletsky S, Tsvitbaum N, Wadepuhl M, Thomsen T, Darius H. The reliability of QTc interval assessment. Bonn - Germany: 2003 Annual Meeting of the Arbeitsgemeinschaft für Angewandte Humanpharmakologie (Association for Applied Human Pharmacology), 23-25 February 2003.

  61. Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 2003; 83: 965-1016.

  62. Lucker PW, Birkel M, Hey B, Loose I, Schaefer A. Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. Methods Find Exp Clin Pharmacol 2003; 25(8):631-637.

  63. Lucker PW, Birkel M, Hey B, Loose I, Schaefer A. Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers. Arzneimittelforschung 2003; 53(4):260-265.

  64. Meyer T, Weuthen T, Berkel E, Timmer W, Herpich C, Weber N. Gamma-scintigraphic evaluation of the delivered dose, lung deposition rate and distribution pattern of 99mTc-labelled tiotropium via dry powder inhaler. Poster, 13th ERS Annual Congress, Vienna, Austria, Sept 27-Oct 1, 2003. Abstract. Eur Resp J 2003, 22, Suppl. 45: 475S.

  65. Molter GP, Soltész S, Larsen R, Baumann-Noss S, Biedler A, Silomon M. Haemodynamic effects following preoperative hypervolemic haemodilution with hypertonic hyperoncotic colloid solutions in coronary artery bypass graft surgery. Anaesthesist. Abstract. 2003 Oct; 52(10):905-18. German.

  66. Schultz A, Stuck BA, Feuring M, Hormann K, Wehling M. Novel approaches in the treatment of allergic rhinitis.. Curr Opin Allergy Clin Immunol 2003; 3: 21-7.

  67. Timmer W. Strategies of pediatric testing in the clinical development of new drugs for asthma [Strategien der pädiatrischen Arzneimittelentwicklung in der Indikation Asthma]. Lecture at the Annual Meeting of the Arbeitsgemeinschaft für angewandte Humanpharmakologie [Association for applied human pharmacology] (AGAH e.V.), Februar 23-25, 2003, Bonn.

  68. Zahn R, Fraiture B, Siegler KE, Schneider S, Gitt AK, Seidl K, Gandjour A, Wendland G, Vogt S, Lauterbach KW, Senges J. Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center. Z Kardiol. 2003 Jun; 92(6):438-44.

  69. Feuring M, Bertsch T, Tran BM, Rossol-Haseroth K, Losel R, Tillmann HC, Schultz A, Weigel M, Wehling M. Seminal plasma hormone concentration after oral application of progesterone. Int J Clin Pharmacol 2002; Ther 40: 47-52.

  70. Feuring M, Christ M, Roell A, Schueller P, Losel R, Dempfle CE, Schultz A, Wehling M. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002; 13: 443-7.

  71. Frilling B, Zahn R, Fraiture B, Mark B, Donges K, Becker T, Siegler KE, Seidl K, Rustige J, Senges J. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol. 2002 Feb 15; 89(4):450-2.

  72. Goss PE, Thomsen T, Banke-Bochita J, Lowery C, D'Angelo P, Asnis A. A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy pos. 02 Dec 11; San Antonio - Texas: 25th Annual San Antonio Breast Cancer Symposium, December 11-14, 2002.

  73. Hartmann M, Timmer W. Modelle zur Bestimmung der intragastralen Azidität [Models for determination of intragastric acidity]. In: Kompendium der Klinischen Pharmakologie, AGAH Schriftenreihe; Herrlinger C, Cawello W (ed.), Shaker Verlag, Aachen 2002.

  74. Senges JC, Becker R, Schreiner KD, Bauer A, Weretka S, Siegler K, Kuebler W, Schoels W. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. Pacing Clin Electrophysiol. 2002 Feb; 25(2):183-90.

  75. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002; 53(3):232-237.

  76. Thomsen T, Eckl KM. Praktische, klinisch-pharmakologische Tätigkeit am Probanden und Patienten (Phase I). In: Herrlinger C, Cawello W, editors. Kompendium der Klinischen Pharmakologie. Aachen: Shaker Verlag; 2002. 517-554.

  77. Timmer W. Klinische Entwicklung von Tiotropium: Vorstellung von Studienergebnissen [Clinical development of tiotropium: presentation of study results]. Lecture on the occasion of the workshop „Fortschritte bei der inhalativen Behandlung von COPD“, VII. Deutsches Aerosol-Therapie-Seminar (German Aerosol Therapy Seminar), Kassel, November 8-9, 2002.

  78. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol. 2002 Mar; 42(3):297-303.

  79. van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002 Jun; 53(6):589-595.

  80. Vanscheidt W, Jost V, Wolna P, Lücker PW, Müller A, Theurer C, Patz B, Grützner KI. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung 2002; 52(4):243-50.

  81. Weinbrenner A, Hüneke D, Zschiesche M, Engel G, Timmer W, Steinijans VW, Bethke T, Wurst W, Drollmann A, Kaatz HJ, Siegmund W. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab. 2002 May; 87(5): 2160-3.

  82. Feuring M, Gutfleisch A, Ganschow A, Richter E, Eichler H, Dempfle CE, Tillmann HC, Schultz A, Wehling M. Impact of plasmapheresis on platelet hemostatic capacity in healthy voluntary blood donors detected by the platelet function analyzer PFA-100. Platelets 2001; 12: 236-40.

  83. Fitzl G, Welt K, Wassilew G, Clemens N, Penka K, Mukke N. The influence of hypoxia on the myocardium of experimentally diabetic rats with and without protection by Ginkgo biloba extract. III: Ultrastructural investigations on mitochondria. Exp Toxicol Pathol. 2001 Feb;52(6):557-68.

  84. Junge W, Wilke B, Halabi A, Klein G. Creatinine excretion and creatinine clearance: determination of reference intervals using a specific enymatic and a modified Jaffé method. July 29 – August 2, 2001. AACC/CSCC, Annual Meeting & Clin Lab Expo.

  85. Kienle E, Hillger H, Hübner R, Jost V. Prospektive, randomisierte Studie zur Wirksamkeit und Verträglichkeit des GnRH-Analogons Leuprorelinacetat als 1- und 3-Monats-Depot bei Patientinnen mit Uterus myomatosus. Geburtsh Frauenheilk 2001; 61: 784-787.

  86. Schmidt BM, Kusma M, Feuring M, Timmer W, Neuhäuser M, Bethke T, Stuck BA, Hörmann K, Wehling M. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2001 Oct; 108(4):530-6.

  87. Ullmann U, Lehnfeld R, Bliesath H, Birkel M, Gebbing H, Gräve M, Wolf H. Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers. Int J Clin Pharmacol Ther. 2001 Jun; 39(6):271-6.

  88. Hartmann M, Schulz HU, Krupp S, Schuerer M, Huber R, Luehmann R, Bethke T, Timmer W, Wurst W. Pantoprazole Lacks Interaction with the NSAID naproxen in man. Poster, Jahreskongreß für Klinische Pharmakologie, Berlin, 5.-7. October 2000; Abstract: Eur J Clin Pharmacol 2000, 56 (7): A17.

  89. Herberg KW, Neukirchen B, Timmer W, Diedrich A, Bethke T, Hauns B, Wurst W. Treatment with the new PDE4 inhibitor roflumilast does noch impair vigilance and traffic safety. Poster, Jahreskongreß für Klinische Pharmakologie, Berlin, 5.-7. October 2000. Abstract: Eur J Clin Pharmacol 2000, 56 (7): A29.

  90. Lücker PW, Jost V, Wolna P, Patz B, Theurer C. Efficacy and safety of butcher’s broom rhizoma extract (ruscus aculeatus l.) compared to placebo in patients suffering from chronic venous insufficiency. Abstract, 3rd International Congress on Phytomedicine, Munich, Germany, 11-13 October 2000.

  91. Fitzl G, Welt K, Martin R, Dettmer D, Hermsdorf T, Clemens N, Konig S. The influence of hypoxia on the myocardium of experimentally diabetic rats with and without protection by Ginkgo biloba extract. I. Ultrastructural and biochemical investigations on cardiomyocytes. Exp Toxicol Pathol. 2000 Oct; 52(5):419-30.

  92. Popken G, Schultze-Seemann W, Seiler KU, Birkel M, Wetterauer U. Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. Eur J Clin Pharmacol 2000; 56(3):241-246.

  93. Timmer W, Bethke T, Hartmann M, Baumgartner A, Eichberger C, Hauns B, Steinijans VW, Wurst W. Treatment with therapeutic Doses of the new PDE4 inhibitor roflumilast does not influence cardiovascular function. Poster, Jahreskongreß für Klinische Pharmakologie, Berlin, 5.-7. October 2000. Abstract. Eur J Clin Pharmacol 2000, 56 (7): A29.

  94. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W. The clinical efficacy of the new PDE4 inhibitor roflumilast in exercise-induced asthma is accompanied by suppression of LPS-stimulated TNF-α levels. Poster, Annual Congress for Clinical Pharmacology, Berlin, October 5-7, 2000. Abstract: Eur J Clin Pharmacol 2000, 56 (7): A29.

  95. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks. Lecture at the 96th International Conference of the American Thoracic Society, May 5-10, 2000, Toronto. Abstract: Amer J Respir Crit Care Med 2000, 161 (3, Part 2): A505.

  96. Timmer W, Schmidt BM, Georgens AC, Steinijans VW, Bethke T, Hörmann K, Wehling M. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. Poster, 96th Inernational Conference of the American Thoracic Society, May 5-10, 2000, Toronto. Abstract: Amer J Respir Crit Care Med 2000, 161 (3, Part 2): A323.

  97. Timmer W, Weinbrenner A, Hüneke D, Zschiesche M, Engel G, Wurst W, Siegmund W. Repeated inhalation of the new topical steroid ciclesonide does not lead to adrenal suppression in healthy subjects. Poster, 96th International Conference of the American Thoracic Society, May 5-10, 2000, Toronto. Abstract: Amer J Respir Crit Care Med 2000, 161(3, Part 2): A776.

  98. Faiss S, Räth U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999 Sep-Oct;60(5):469-76.

  99. Bachus R, Bickel U, Thomsen T, Roots I, Kewitz H. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9:661-668.

  100. Bethke T, Heinze H, Timmer W, Hartmann M, Hauschke D, Zech K, Wurst W. Interaction of budipine and metoprolol in healthy subjects. Poster, Jahreskongreß für Klinische Pharmakologie, Berlin, 10.-12. Juni 1999. Abstract: Eur J Clin Pharmacol 1999, 55 (3): A23.

  101. Clemens N. Future-oriented clinical research in Germany. The role of ethics committees. Dtsch Med Wochenschr 1999; 124(34-35):A17.

  102. Dingemanse J, Halabi A, Kleinbloesem CH, Heinig R, Blume H. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment. Ther Drug Monit 1999; 21(3):310-316.

  103. Eckl KM, Thomsen T, Römer A, Dehn A. Terfenadine induced QTc-Prolongation in healthy subjects - a safety model. Eur J Clin Pharmacol 1999; 55 (No. 108).

  104. Georgens AC, Schmidt BMW, Timmer W, Mattinger C, Steinijans VW, Hilt M, Freitag B, Christ M, Feuring M, Bethke T, Wurst W, Hörmann K, Wehling M. Efficacy of the new topical steroid ciclesonide in the treatment of allergic rhinitis. Poster, Jahreskongreß für Klinische Pharmakologie, Berlin, 10.-12. Juni 1999. Abstract: Eur J Clin Pharmacol 1999, 55 (3): A36.

  105. Rost KL, Fuhr U, Thomsen T, Zaigler M, Brockmöller J, Bohnemeier H, Roots I. Omeprazole weakly inhibits CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999 Nov; 37(11):567-74.

  106. Schmidt BM, Timmer W, Georgens AC, Hilt M, Mattinger C, Wurst W, Hörmann K, Wehling M. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin Pharmacol. 1999 Oct; 39(10):1062-9.

  107. Schmidt BMW, Timmer W, Georgens A, Freitag B, Becker S, Steinijans VW, Hilt M, Christ M, Feuring M, Bethke T, Wurst W, Hörmann K, Wehling M. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. Poster, 40. Frühjahrstagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz, 9.-11. März 1999.Abstract: Arch Pharmacol 1999, 359 (3) Suppl.: 477.

  108. Thomsen T, Brockmüller J, Popescu C, Hucke HP, Eckl KM, Roots I. No effect of liver impairment on the pharmacokinetics of levetiracetam. Eur J Clin Pharmacol 1999; 55:No. 59.

  109. Thomsen T, Brockmüller J, Eckl KM, Wittstock M, Roots I. Usefulness of Child Pugh classification to select patients with liver impairment for clinical studies. Jerusalem - Israel: 3rd Congress of the European Association for Clinical Pharmacology, October 3-8, 1999; 1999.

  110. Wadepuhl M, Thomsen T, Drachenberg J, Möller M, Eckl KM. Tolerability and immunological activity of monophosphoryl lipid A in specific immunotherapy. J Clin Pharmacol 1999; 39(9):No. 47.

  111. Hartmann M, Ehrlich A, Fuder H, Lühmann R, Emeklibas S, Timmer W, Wurst W, Lücker PW. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther. 1998 Oct; 12(10):1027-32.

  112. Kleist P, Suzuki Y, Thomsen T, Möller M, Römer A, Hucke HP, Kurowski M, Eckl KM. Voglibose has no effect on the pharmacokinetics of hydrochlorothiazide. Eur J Clin Pharmacol. 1998 May; 54(3):273-4.

  113. Stucki M, Schnorf J, Hustinx H, Gerber H, Lerch PG, Halabi A, Kleinbloesem CH, Morell A. Anti-D immunoglobin in Rh(D) negative volunteers: clearance of Rh(D) positive red cells and kinetics of serum anti-D levels Transfus Clin Biol 1998; 5: 180 – 188.

  114. Timmer W, Bethke T. Kurzbewertung: Chloralhydrat [Executive summary: Chloralhydrate]. Arzneimittel-, Therapie-Kritik, 1998/Episode 4. Internistische Praxis 38 (4): 915-917.

  115. Weinbrenner A, Hüneke D, Zschiesche M, Engel G, Timmer W, Steinijans VW, BethkeT, Wurst W, Drollmann A, Kaatz HJ, Siegmund W. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. Poster, 8th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Greifswald, 10-12 September 1998. Abstract: Eur J Clin Pharmacol 1998, 54 (6): A 27.

  116. Grosche J, Grimm D, Clemens N, Reichenbach A. Retinal light damage vs. normal aging of rats: altered morphology, intermediate filament expression, and nuclear organization of Muller (glial) cells. J Hirnforsch. 1997;38(4):459-70.

  117. Bogner JR, Boerner D, Muhlhofer A, Thoma-Greber E, Herrmann DB, Hoegl L, Roecken M, Jost V, Goebel FD. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). Antivir Ther 1997 Dec; 2(4):249-256.

  118. Eckl KM, Thomsen T, Möller M, Violet I, Dubois F. The bradycardic effect of the sinuatrial modulator S16257. Eur Heart J 1997; 18(Suppl.):No.P1047.

  119. Eckl KM, Thomsen T, Hucke HP, Kleist P, Suzuki Y, Möller M. Cholestyramine does not impair the effects of voglibose (AO-128) on glucose and insulin. Diabetologia 1997; 40(Suppl. 1):No. 1281.

  120. Fuder H, Stiegler S, Wetzelsberger N, Wieckhorst G, Lange R, Lucker PW. Effect of buffering on pharmacokinetics of ketoprofen enantiomers in man. Br J Clin Pharmacol 1997; 44(6):527-530.

  121. Fuder H. Hartmann M, Wieckhorst G, Ehrlich A, Timmer W, Lühmann R, Wurst W. Pantoprazole is equipotent after oral intake and intravenous administration. Poster; 97th Annual Meeting of the American Gastroenterological Association, May 11-14, Washington, D.D., USA. Abstract: Gastroenterol 1997, 112 (4) (suppl.):A 119.

  122. Fuder H, Kleist P, Birkel M, Ehrlich A, Emeklibas S, Maslak W, Stridde E, Wetzelsberger N, Wieckhorst G, Lücker PW. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Eur J Clin Pharmacol. 1997; 53(2):153-7.

  123. Kleist P, Ehrlich A, Suzuki Y, Timmer W, Wetzelsberger N, Lücker PW, Fuder H. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol. 1997; 53(2):149-52.

  124. Püchler K, Eckl KM, Fritsche L, Renneisen K, Neumayer H, Sierakowski B, Lavrijssen AJC, Thomsen T, Roots I. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment. Br J Clin Pharmacol 1997; 44:531-536.

  125. Thomsen T, Püchler K, Eckl KM, Plenker A, Möller M, Hucke HP. Cardiovascular safety of the monoaminooxidase inhibitor (MAO-I) RS-8359 in combination with intravenous tyramine. Eur J Clin Pharmacol 1997; 52(Suppl.):No. 436.

  126. Thomsen T, Eckl KM, Römer A, Peck CC, Dehn A. Terfenadine drug interaction. PK/PD and non-responders. Ulm - Germany: Spring meeting AGAH, 30.01.-05.02.1997; 1997.

  127. Timmer W, Wehling M, Theiss U. 24-hour recording of intragastric pH in clinical trials: preconditions, methodology, and standardization strategies. J Clin Pharmacol. 1997 Jan; 37(1 Suppl):34S-39S.

  128. Eckl KM, Thomsen T, Römer A, Hucke HP, Kurowski M, Kleist P et al. No interaction of the disaccharidase inhibitor AO-128 (Voglibose) with hydrochlorothiazide. Naunyn Schmiedebergs Arch Pharmakol 1996; 354(Suppl. 1):R30

  129. Eckl KM, Römer A, Kleist P, Suzuki Y, Thomsen T. Pharmacokinetics of captopril unchanged by concomitant medication of voglibose (AO-128). Acta Physiologica Pharmacologica et Therapeutica Latinoamericano 1996; P 242 No. 556.

  130. Ehrlich A, Fuder H, Hartmann M, Wieckhorst G, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol. 1996; 51(3-4):277-81.

  131. Fuder H, Kleist P, Ehrlich A, Timmer W, Suzuki Y, Birkel M. No Pharmacokinetic interaction between the alpha-glucosidase inhibitor voglibose (AO-128) and glibenclamide in healthy subjects. Poster. Abstract: Arch Pharmacol 1996, 354 (4), Suppl 1: R31.

  132. Püchler K, Eckl KM, Fritsche L, Renneisen K, Neumayer H, Sierakowski B, Lavrijssen AJC, Thomsen T. Repeat dose pharmacokinetics of temocapril (T) in renally impaired subjects. Acta Physiologica Pharmacologica et Therapeutica Latinoamericano 1996; 242 No. 555.

  133. Rehn D, Unkauf M, Klein P, Jost V, Lucker PW. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. Arzneimittelforschung 1996 May; 46(5):483-487.

  134. Rost L, Bohnemeier H, Thomsen T, Roots I. Inhibition of CYP1A2 by omeprazole in man: Dependence on dose and CYP2C19 Genotype. Naunyn Schmiedebergs Arch Pharmakol 1996; 353(Suppl.):R148.

  135. Theiß U, Timmer W, Lücker PW. Die intragastrale Langzeit-pH-Metrie [long-term intragastric pH measurements]. Abstract: Kongressband (summary of abstracts), 5th Annual Meeting of the AGAH, Februar 4-6, 1 1996, Berlin.

  136. Thomsen T, Eckl KM, Möller M, Knieps-Massong W, Hucke HP. Evaluation of the pharmacokinetics and pharmacodynamics of Thyreocomb N, a new galenic formulation of thyroxine and iodide. Naunyn Schmiedebergs Arch Pharmakol 1996; 353(Suppl.):R 146.

  137. Thomsen T, Eckl KM, Möller M, Drachenberg J. Keine Sensibilisierung durch multiple Dosen von modifiziertem Allergen (Allergoid) bei gesunden Probanden. Allergo J 1996; 5:P33.

  138. Thomsen T, Eckl KM, Möller M, Hucke HP. Noninvasive continuous blood pressure measurement as a tool for estimating the interaction of monoaminooxidase inhibitors with tyramine. Naunyn Schmiedebergs Arch Pharmakol 1996; 353(Suppl.):R 140.

  139. Thomsen T, Eckl KM, Möller M, Knieps-Massong W, Hucke HP, Schlieper P. Relative Bioverfügbarkeit einer neuen galenischen Formulierung von Thyroxin und Iodid: Thyreocomb N. Therapiewoche 1996; 46(3).

  140. Timmer W, Kleist P, Ripke H. Lücker PW, Fuder H. Intra- and interindividual response to multiple dose treatment with four lansoprazole dosage regimen and a reference treatment with omeprazole. Poster, 6th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Dresden, 5-7 September 1996. Abstract: Eur J Clin Pharmacol 1996, 60 (6): 555.

  141. Ehrlich A, Fuder H, Hartmann M, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Pantoprazole lacks pharmacokinetic and pharmacodynamic interaction with phenprocoumon in man. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 128.

  142. Ehrlich A, Fuder H, Hartmann M, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Lack of pharmacokinetic and pharmacodynamic interaction of pantoprazole and phenprocoumon in man. Poster, 95th Annual Meeting of the American Gastroenterological Association, May 14-17, San Diego, USA. Abstract: Gastroenterol 1995, 108 (4) (suppl.): A 86.

  143. Fuder H, Hartmann M, Timmer W, Lühmann R, Wieckhorst G, Huber R, Bliesath H, Wurst W, Postius S, Radtke KW, Lücker PW. First administration to man of the new acid pump antagonist BY841: tolerability, safety and pH—metry. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 127-A 128.

  144. Fuder H, Hartmann M, Timmer W, Lühmann R, Wieckhorst G, Huber R, Bliesath H, Wurst W, Radtke KW, Lücker PW. Repeated oral administration of the acid pump antagonist BY841. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 128.

  145. Fuder H, Hartmann M, Timmer W, Lühmann R, Wieckhorst G, Huber R, Bliesath H, Wurst W, Postius S, Radtke KW, Lücker PW. First administration to man of the new reversible proton pump inhibitor BY841: tolerability, safety and pH-metry. Poster, 95th Annual Meeting of the American Gastroenterological Association, May 14-17, San Diego, USA. Abstract: Gastroenterol 1995, 108 (4) (suppl.): A 96.

  146. Molter G, Larsen R, Baumann-Noß S, Kalweit G, Grundmann U. Hämodynamische Effekte hypertoner Dextran-Lösung in der Coronarchirugie. Anaesthesist 44 (Suppl. 1): S. 62. Abstract 1995.

  147. Molter G, Larsen R, Grundmann U, Kalweit G, Rose S, Baumann-Noß S. Immunologic reactions during myorcardial revascularization after haemodilution with colloid solutions. BriJ. Anaesthesia 74 (Suppl 2): 37. Abstract 1995.

  148. Molter G, Larsen R, Kleinschmitt S, Kalweit G, Baumann-Noß S, Rose S. Immunologische Reaktionen bei Coronar-Bypass-Operationen unter dem Einfluß hyperton-hyperonkotischer Kolloide. Anaesthesist 44 (Suppl. 1): S. 288. Abstract 1995.

  149. Ripke H, Fuder H, Kleist P, Timmer W, Wieckhorst G, Ehrlich A, Lücker PW. Intragastric pH under various dosage regimens of lansoprazole as compared to a reference treatment with omeprazole. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 23.

  150. Stiegler S, Birkel M, Jost V, Lange R, Lucker PW, Wetzelsberger N. Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets. Methods Find Exp Clin Pharmacol 1995 Mar; 17(2):129-134.

  151. Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lücker PW, Fuder H. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Methods Find Exp Clin Pharmacol. 1995 Sep; 17(7):489-95.

  152. Wetzelsberger N, Birkel M, Fuder H, Lücker PW, Stiegler S, Scheithauer S, Thümmler D. Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. Methods Find Exp Clin Pharmacol. 1995 Apr; 17(3):185-91.

  153. Kleinschmitt S, Nilles C, Lange O, Stöckl W, Baumann-Noß S. Zusatz von Clonidin zur intravenösen Regionalanästhesie der oberen Extremität. Anaesthesist Suppl. 1, Juni 1994, S. 257. Abstract.

  154. Theiß U, Timmer W, Wieckhorst G, Jost V, Lücker PW. Study on the relative bioavailability of dolcontral® 100 mg supositories as compared to an equimolar aqueous solution of pethidine*HCI in healthy volunteers. Poster, 35. Frühjahrstagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz, 15.-17. März 1994. Abstract: Arch Pharmacol 1994, 349 (suppl.): R 148.

  155. Blume H, Scheidel B, Siewert M, Halabi A, Kirch W. Bioverfügbarkeit von acetylsäurehaltigen Analgetika. Pharmazie 1993; 24: 26-40.

  156. Halabi A, Kirch W. Twenty-four-hour hemodynamic effects of two different dihydropyridine derivatives assessed by noninvasive methods in patients with congestive heart failure.American Journal of Noninvasive Cardiology 1993; 7: 180-185.

  157. Halabi A, Moerchel J, Gronow G, Buhr C, Kirch W. Ibopamine in patients with congestive heart failure and different degrees of renal function. British Journal of Clinical Pharmacology (eingereicht) 1993.

  158. Halabi A, Nokhodian A, Kirch W. Bunazosin in patients with impaired hepatic or renal function. Eur J Drug Metab Pharmacokinet 1993; 18(3): 309-313.

  159. Hinrichsen H, Halabi A, Fuhrmann G, Kirch W. Dose-dependent heart rate reducing effect of nizatidine, a histamine H2-receptor antagonist. British Journal of Clinical Pharmacology 1993; 35: 461-466.

  160. Mescheder A, Ebert U, Halabi A, Kirch W. Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine. European Journal of Clinical Pharmacology 1993; 45 (2): 151-156.

  161. Mescheder A, Halabi A, Nokhodian A, Al-Hamdan Y, Kirch W. Antihypertensive activity, cardiac performance and pharmacokinetics of bunazosin, a novel adrenoceptor antagonist, in patients with normal and impaired renal function. Drug Invest 1993; 6: 263-270.

  162. Nokhodian A, Santos S, Halabi A, Kirch W. Digitoxin and its metabolites in patients with liver cirrhosis. European Journal of Drug Metabolism and Pharmacokinetics 1993; 18: 207-213.

  163. Theiß U, Timmer W, Wieckhorst G, Macciocchi A, Wetzelsberger N. Investigation into a possible drug-drug interaction between warfarin and nimesulide in healthy volunteers. Meth Find Exp Clin Pharmacol 1993, 15(9): 629-635.

  164. Timmer W, Theiß U, Rosenkranz B, Wieckhorst G, Birkel M, Lücker PW. Study on the relative bioavailability of dolantin® suppositories as compared to dolantin® drops in healthy volunteers. Poster, 5. Wintertagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, Hannover, 1.-3. Dez. 1993. Abstract: Arch. Pharmacol. 1993, 348 (suppl.): R 171.

  165. Eckl KM, Stoeter M, Möller M, Collie H. Die periphervasodilatorischen Eigenschaften von BRL 38227 - Nachweis an gesunden Probanden. Zürich - Schweiz: Zweite gemeinsame Tagung Deutsche Liga zur Bekämpfung des hohen Blutdruckes und Schweizerische Vereinigung gegen hohen Blutdruck, 26.-28.11.1992.; 1992.

  166. Eckl KM, Stoeter M, Möller M, Wargenau M. Conjunctival capillaroscopy as a method for investigation of drugs with vasodilative properties. Naunyn Schmiedebergs Archives of Pharmacology 345. 1992.

  167. Halabi A, Kirch W. Cardiovascular effects of omeprazole and famotidine. Scandinavian Journal of Gastroenterology 1992; 27: 753-756.

  168. Halabi A, Nokhodian A, Kirch W. Haemodynamic effects of roxatidine, an H2-receptor antagonist. Clin Investig 1992 Feb; 70(2):118-21.

  169. Hinrichsen H, Halabi A, Kirch W. Haemodynamic effects of H2-receptor antagonists. Review. European Journal of clinical Investigation 1992 Jan; 22(1):9-18.

  170. Hock C, Jonitz L, Meller I, Bondy B, Bickel U, Thomsen T, Engel RR. Galanthamine as a useful therapeutic agent in Alzheimer's disease. Neurobiology of Aging 13, 130. 1992.

  171. Holl G, Straschill M, Thomsen T, Fischer JP, Kewitz H. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials. Electroencephal Clin Neurophysiol 1992; 82:445-452.

  172. Jost V, Kuhn I, Rogalla K, Theiss U, Lucker PW. Gastric potential difference measurement as a quantification of gastrointestinal tolerability comparing a buffered acetylsalicylic acid formulation versus plain acetylsalicylic acid. Arzneimittelforschung 1992; 42(5):650-653.

  173. Kirch W, Halabi A, Hinrichsen H. Haemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clinical Pharmacology and Therapeutics 1992; 51:325-333.

  174. Kirch W, Nokhodian A, Halabi A, Weidinger G. Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. Eur J Drug Metab Pharmacokinet 1992 Jan-Mar; 17(1):33-8.

  175. Kuhn I, Jost V, Wieckhorst G, Theiss U, Lücker PW. Renal elimination of magnesium as a parameter of bioavailability of oral magnesium therapy. Methods Find Exp Clin Pharmacol. 1992 May; 14(4):269-72. Erratum in: Methods Find Exp Clin Pharmacol 1993 Jun; 15(5): following 328.

  176. Palm S, Hinrichsen H, Barth J, Halabi A, Ferstl R, Tolk J, Kirsten R, Kirch W. Modulation of lymphozyte subsets due to psychological stress in patients with rheumatoid arthritis. European Journal of Clinical Investigation 1992; 22: 26 - 29.

  177. Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez AJ, Welker HA, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 1992 Sep; 52(3):314-23.

  178. Stoeter M, Möller M, Eckl KM, Wargenau M. Conjunctival capillaroscopy allows to quantify vasodilative effects of nifedipine, captopril, and moxaverine. Barcelona - Spain: 14th Congress of the European Society of Cardiology, 30.08.-03.09.1992; 1992.

  179. Thomsen T. Selective inhibition of human acetylcholinesterase in vitro by S-9977-2. Neurobiology of Aging 13, 132. 1992.

  180. Thomsen T, Allen A, Sourgens H, Köster FE, Greb WH, Brett M, Collie H, Kurth J. Pharmacokinetics of granisetron (BRL 43694A) in man before and after enzyme induction by phenobarbital. Yokohama - Japan: 5th World Conference on Clinical Pharmacology and Therapeutics; 1992.

  181. Bachus R, Thomsen T, Bickel U, Kewitz H. Galanthamine O-demethylation in man. Naunyn Schmiedebergs Archives of Pharmacology 344[Suppl.], R89. 1991.

  182. Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M, Kewitz H. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther. 1991 Oct; 50(4):420-8.

  183. Bickel U, Thomsen T, Fischer JP, Weber W, Kewitz H. Galanthamine: pharmacokinetics, tissue distribution and brain cholinesterase inhibition in mice. Neuropharmacol 1991; 30:447-454.

  184. Köppel C, Thomsen T, Heinemeyer G, Roots I. Acute poisoning with bromofosmethyl. J Toxicol Clin Toxicol 1991; 29:203-207.

  185. Linde M, Halabi A. Kalziumantagonisten-negative Inotropie und Kardioprotektion. Herz und Gefässe 1991; 11: 470-476.

  186. Thomsen T, Kaden B, Fischer JP, Bickel U, Barz H, Cervos-Navarro J, Kewitz H. Inhibition of acetylcholinesterase activity by galanthamine, physostigmine and tacrine in human brain tissue and erythrocytes. Eur J Clin Pharmacol 1991; 29:487-492.

  187. Thomsen T, Bachus R, Bickel U, Kewitz H. In vitro inhibition of human cholinesterases by O-demethyl-galanthamine. Naunyn Schmiedebergs Archives of Pharmacology 344[Suppl.]. 1991.

  188. Thomsen T, Zendeh B, Fischer JP, Kewitz H. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol 1991; 41:139-141.

  189. Thomsen T, Fischer JP, Bickel U, Kewitz H. Zur Wirkung verschiedener Cholinesterase Hemmstoffe auf die menschliche Acetylcholinesterase (EC 3.1.1.7) in Erythrocyten und Hirngewebe. Deutsche Gesellschaft für Innere Medizin, 97. Tagung Wiesbaden, 6.-10. April 1991. Klinische Wochenschrift 69[Suppl.], 166. 1991. Ref Type: Abstract.

  190. Thomsen T, Fischer JP, Bickel U, Kaden B, Kewitz H. Inhibition of cholinesterases in vitro in human brain and erythrocytes by galanthamine. Spring Meeting DGPT, Mainz, March 12-15, 1991. Naunyn Schmiedebergs Archives of Pharmacology Suppl. to Vol. 343, R 130. 1991. Ref Type: Abstract.

  191. Thomsen T, Kewitz H, Bickel U, Straschill M, Holl G. Preclinical and clinical studies with galanthamine. In: Giacobini E, Becker R, editors. Pharmacological basis of cholinergic therapy in Alzheimer disease. Boston: Birkhäuser Inc.; 1991. 329-336.

  192. Scheid P, Siffert W, Mückenhoff K, Pelster B, Clemens N. Significance of Carbonic Anhydrase in the Function of Skeletal Muscle. In: Deecke L, Eccles JC, Mountcastle VB (Eds): From Neuron to Action. An Appraisal of Fundamental and Clinical Research. Springer, Berlin Heidelberg, 1990.

  193. Bickel U, Thomsen T, Fischer JP, Kewitz H. Galanthamine pharmacokinetics and cholinesterase inhibition in mice. Eur J Pharmacol 1990; 183:1945.

  194. Bickel U, Thomsen T, Fischer JP, Pleul O. Pharmacokinetics and cholinesterase inhibition of galanthamine in mice in vitro and ex vivo. Naunyn Schmiedebergs Arch Pharmakol 1990; Suppl. to Vol. 341:R 81.

  195. Bickel U, Thomsen T, Fischer JP, Kewitz H. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. 2. International Conference on Alzheimer’s Disease & Related Disorders, Toronto, Canada, July 15-20, 1990. Neurobiology of Aging 11, 345-346. 1990.

  196. Clemens N, Siffert W, Scheid P. Thrombin-induced cytosolic alkalinization in human platelets occurs without an apparent involvement of HCO3-/Cl- exchange. Pflugers Arch 1990; 416(1-2):68-73.

  197. Halabi A, Endell W, Halabi I, Kirch W. Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension. Journal of Cardiovascular Pharmacology 1990; 16: 81-85.

  198. Halabi A, Kirch W. Negative chronotropic effects of nizatidine. Gut 1990; 32: 630-634.

  199. Halabi A, Linde M, Saathoff H, Nokhodian A, Dylewicz P, Kirch W. Hemodynamic effects of diltiazem and nitrendipine assessed by noninvasive methods in patients with congestive heart failure. American Journal of Noninvasive Cardiology 1990; 4: 60-64.

  200. Halabi A, Wüstefeld B, Zurborn KH, Kaiser P, Kirch W. Celiprolol bei Hypertonikern. Zirkadiane Blutdruckwerte und hämostaseologische Parameter im Verlauf der Therapie. Münchener Medizinische Wochenschrift 1990; 132:167-170.

  201. Hinrichsen H, Halabi A, Kirch W. Hemodynamic effects of different H2-receptor antagonists. Clinical Pharmacology and Therapeutics 1990; 48: 302-308.

  202. Holl G, Straschill M, Thomsen T, Fischer JP, Kewitz H. Effect of the cholinesterase inhibiting substance galanthamine on EEG and visual evoked potentials. 1990 Jun 28; Göteborg- Sweden: Symposium of the International Pharmaco EEG-Group; 1990.

  203. Kirch W, Milferstädt S, Halabi A, Rocher I, Efthymiopoulos C, Jung L. Interaction of teralol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. Cardiovascular Drugs and Therapy 1990; 4: 487-492.

  204. Linde M, Halabi A, Kirch W. Einsatzmöglichkeiten der Impedankardiographie für hämodynamische Fragestellungen in der klinischen Pharmakologie 1990; CorVas 5: 221-224.

  205. Thomsen T, Bickel U, Fischer JP, Kewitz H. Bioavailability, pharmacokinetics and pharmacodynamics of galanthamine hydrobromide in human volunteers. Kyoto - Japan: 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum; 1990. Abstracts II, 234.

  206. Thomsen T, Bickel U, Fischer JP, Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39:603-605.

  207. Thomsen T, Bickel U, Fischer JP, Kewitz H. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1990; 1:46-51.

  208. Thomsen T, Fischer JP, Bickel U, Kewitz H. Stereoselectivity of the inhibitory effect of galanthamine on human acetylcholinesterase. European Society for Neurochemistry, 8th General Meeting, Leipzig, 23.-28.07.1990. Abstracts P 13.10, 108; 1990.

  209. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46:1553-1558.

  210. Bickel U, Thomsen T, Fischer JP, Kewitz H. Galanthamine: pharmacokinetics and inhibition of cholinesterases in humans. In: Kewitz H, Thomsen T, Bickel U, (eds): Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Klinische Pharmakologie. München; San Francisco: W. Zuckschwerdt Verlag 1989; 280-283.

  211. Cuprunov M, Fink P, Drakoulis N, Nitz M, Thomsen T, Roots I. Evaluation of a new dihydropyridine calcium channel blocker, diperdipine, in four phase-I studies. Florence - Italy: 4th International Symposium on Calcium Antagonists, 25.-27.05.1989; 1989.

  212. Cuprunov M, Thomsen T, Fink P, Roots I. Phase-I evaluation of diperdipine, a new dihydroperidine calcium channel blocker. Eur J Clin Pharmacol 1989; 36: Suppl.: A 336.

  213. Halabi A, Linde M, Zeidler H, König J, Kirch W. Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives. Cardiovascular Drugs and Therapy 1989; 3: 441-443.

  214. Halabi A, Zurborn KH, Kaiser P, Proppe D, Kirch W. Haemostaseological parameters and circadian blood pressure values in hypertensives on chronic celiprolol administration. 23rd Annual Scientific Meeting, Athens, 19-22 April 1989. Europ J Clin Invest 19: A44, 242; 1989.

  215. Halabi I, Gebühr U, Nokhodian A, Linde M, Halabi A, Kirch W. Hemodynamic measurements on different doses of brefanolol, an alpha- and beta- blocking agent. IV World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, 23-28 July 1989. Euro J Clin Pharmacol 36: (Suppl.): A136, PP02.07; 1989.

  216. Kirch W, Halabi A, Ohnhaus EE. Negative effects of famotidine on cardiac performance assessed by non-invasive hemodynamic measurements. Gastroenterology 1989; 96: 1388-1393.

  217. Kirch W, Nokhodian A, Halabi A, Linde M, Dylewicz P. Diltiazem and nitrendipine. Comparison of their haemodynamic effects. 18th Annual Meeting of the American College of Clinical Pharmacology, 11-14 October 1989. J Clin Pharmacol 290:839; 1989.

  218. Kirch W, Nokhodian A, Schacht A, Halabi A. Effects of anipamil on renal function in hypertensives. IV World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, 23-28 July 1989. Euro J Clin Pharmacol 36: (Suppl.): A86, OP28.03; 1989.

  219. Nokhodian A, Halabi A, Kirch W. Barucainid bei Patienten mit normaler und eingeschränkter Nierenfunktion 1989. CorVas 4: 105-108.

  220. Nokhodian A, Linde M, Halabi A, Kirch W. Influence of barucainide on renal function and hemodynamic parameters in patients with kidney disease. IV World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, 23-28 July 1989. Euro J Clin Pharmacol 36: (Suppl.): A203, PP06.59; 1989.

  221. Pleul O, Rost L, Thomsen T, Kewitz H. Increase of prostaglandins in rat brain by tetrahydroaminoacridine or galanthamine. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag 1989; 288-291.

  222. Pleul O, Rost L, Bickel U, Thomsen T. Are prostaglandins an indicator of acetylcholine release in the brain in vivo? IVth World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, July 23-28, 1989. Eur J Clin Pharmacol; 36: Suppl:A78.

  223. Pleul O, Rost L, Thomsen T, Kewitz H. On the correlation of acetylcholine (ACh) and prostaglandin E2 (PGE2) levels in the rat brain after tetrahydroacridine (THA). Naunyn Schmiedebergs Archives of Pharmacology Suppl. to Vol. 339, R 85. 1989.

  224. Pleul O, Rost L, Thomsen T, Weber W, Kewitz H. Correlation between blood and tissue levels of tetrahydroaminoacridine, cholinesterase inhibition and acetylcholine increase in the brain. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag; 1989. 292-297.

  225. Segerling M, Hoffmann K, Hupfeld B, Clemens N. Student survey on the topic of AIDS in the city of Bochum April 1988. Offentl Gesundheitswes 1989; 51(7):331-334.

  226. Thomsen T, Kewitz H. Galanthamine treatment in senile dementia of Alzheimer's type. A case report. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag 1989; 238-241.

  227. Thomsen T, Kewitz H. Comparison of acetyl- (EC 3.1.1.7, AChE) and butyryl- (EC 3.1.1.8, BuChE) cholinesterase inhibition as due to reversible enzyme inhibitors. 8th International Congress of Clinical Enzymology, May 30 – June 1, 1989, Toronto, Canada. Clin Biochem; 22:411.

  228. Thomsen T, Bickel U, Kewitz H. Pharmacokinetic and pharmacodynamic data for galanthamine in the treatment of Alzheimer's disease. Berlin (West): Jahrestagung der Deutschen Gesellschaft für Klinische Chemie, October 8-11, 1989, Berlin (West). (Abstract): J Clin Chem Clin Biochem 27:769 (1989).

  229. Thomsen T, Kewitz H, Pleul O. A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme 1989; 42:219-224.

  230. Thomsen T, Zendeh B, Bickel U, Kewitz H. Inhibition of acetyl- and butyrylcholinesterase as induced by various reversible enzyme inhibitors in vitro. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag 1989; 284-292877.

  231. Cuprunov M, Thomsen T, Fink P, Scheiffele R, Heger-Mahn D, Weber W, Rost L, Roots I. Tolerance of a new dihydroperidine Ca++- channel blocker, diperdipine, in healthy volunteers. Naunyn Schmiedebergs Arch Pharmakol 1988; Suppl. to Vol. 338:R79.

  232. Daldrup T, Thomsen T, Reudenbach G. Cannabiskonsum – Nachweisbarkeitsdauer, zeitlicher Verlauf, forensische Bedeutung. In: Arnold W, Poser WE, Möller MR (eds). Suchtkrankheiten. Diagnose, Therapie und analytischer Nachweis. Springer, Berlin 1988; pp 39-51.

  233. Davies BE, Eckl KM, Greb WH, Mellows G, Thomsen T. The pharmacokinetics of BRL 34915, a new antihypertensive agent, in healthy male subjects. Br J Clin Pharmacol 1988; 25:136-137.

  234. Greb WH, Buscher G, Köster FE, Nix N, Sourgens H, Thomsen T. A study to test the effect of diproteverine on the thyroid in normal volunteers. The British Toxicology Society. 1988.

  235. Halabi A. Der Einfluss von Famotidin auf die Pharmakokinetik von Nifedipin und auf nicht-invasive hämodynamische Parameter. Dissertation med., Kiel 1988.

  236. Halabi A, Ohnhaus EE, Kirch W. Influence of famotidine on non-invasive hemodynamic parameters and nifedipine plasma levels. 22nd Ann. Sci. Meet. Europ. Soc. Clin. Invest. Graz, 21-23 April 1988. Europ J Clin Invest 18: A23, 99; 1988.

  237. Kirch W, Halabi A, Ohnhaus EE. Negative-inotrope Wirkung von Famotidin. Schweizerische Medizinische Wochenschrift 1988; 118: 1912-1916.

  238. Kirch W, Halabi A, Ohnhaus EE. Negative inotropic effects of famotidine. Meeting of the British Society of Pharmacology, London 6.-8.1. 1988. Abstract Volume, Abstr. C79; 1988.

  239. Kirch W, Halabi A, Ohnhaus EE. Negative inotropic effects of famotidine. 89th Meeting of the American Society of Clinical Pharmacology and Therapeutics, San Diego 9-11. March 1988. Clin Pharmacol Ther 43:163 IIA-3; 1988.

  240. Thomsen T, Kewitz H, Pleul O. Estimation of cholinesterase activity (EC 3.1.1.7; 3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring the in vivo effects of reversible inhibitors. J Clin Chem Clin Biochem 1988; 26:469-475.

  241. Thomsen T, Kewitz H, Zendeh B. Effects of various reversible inhibitors on the butyryl (EC 3.1.1.8) and acetyl (EC 3.1.1.7) cholinesterase in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmakol 1988; Suppl. to Vol. 337:R94.

  242. Tolksdorf W, Reinhard F, Hartung M, Baumann S. Vergleichende Untersuchung zu Wirkungen und Nebenwirkungen von Midazolam-Ketamin-Kombinationsnarkosen und einer Thiopental-induzierten Enfluran-Lachgasnarkose für kleinere gynäkolologische Eingriffe. Anaesthesiologie und Intensivmedizin Band 198. Neue Aspekte zu Ketamin in der Anästhesie, Intensiv- und Notfallmedizin. Abstract. Springer-Verlag 1988.

  243. Wetzelsberger N, Lucker PW, Erking W. Internally standardized method for the determination of nalbuphine in human plasma by means of high performance liquid chromatography with electrochemical coulometric detection. Arzneimittelforschung 1988; 38(12):1768-1771.

  244. Darius H, Thomsen T, Schrör K. Cardiovascular actions in vitro and cardioprotective effects in vivo of nileprost, a mixed type PGI2/PGE2 agonist. J Cardiovasc Pharmacol 1987; 10:144-152.

  245. Kirch W, Halabi A, Ohnhaus EE. Negative inotropic effects of famotidine. Lancet 1987; II, 684.

  246. Koch S, Schultz A, Koch N. The production of recombinant HLA-DR beta and invariant chain polypeptides by cDNA expression in E. coli. J Immunol Methods 1987; 103:211-20.

  247. Thomsen T. Kardioprotektive Wirkungen natürlicher und synthetischer Prostaglandine in vivo in Abhängigkeit von der Ischämiedauer. Medizinische Fakultät der Universität zu Köln; 1987.

  248. Tolksdorf W, Baumann S, Heine C, Hettenbach A. Effects and side effects of transdermal scopolamine for premedication in general anesthesia in elderly patients. Anasth Intensivther Notfallmed. Abstract 1986 Dec; 21(6):301-6. German.

  249. Wetzelsberger N, Lucker PW, Erking W. High-pressure liquid chromatographic method for the determination of hydromorphone in human plasma with electrochemical detection. Arzneimittelforschung 1986; 36(11):1707-1710.

  250. Schrör K, Thiemermann C, Thomsen T, Ohlendorf R, Darius H, Gallenkämper W, Smith III EF. Beneficial effects of iloprost (ZK 36374) in experimental myocardial infarction. Mechanisms and their possible significance. In: Schering AG, editor. Iloprost (ZK 36374) a Novel Prostacyclin Analogue in Cardiovascular disease. Paoletti R (ed). Schering AG; 1985.

  251. SmithIII EF, Gallenkämper W, Beckmann R, Thomsen T, Mannesmann G, Schrör K. Early and late administration of a PGI2 analogue, ZK 36374 (Iloprost): Effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 1984; 18:163-173.

  252. Schrör K, Thomsen T, Ohlendorf R, Darius H, Ahland B, Kahlen T. Beneficial effects of a novel prostacyclin analogue, Nileprost or ZK 34798 in acute myocardial ischemia. 5th International Conference on Prostaglandins 1982, Florence: 276.

  253. Schrör K, Thomsen T. Cardioprotective action of a new carbacyclin derivative (ZK 36374) after 2 and 4 h of myocardial infarction. Naunyn Schmiedebergs Arch Pharmakol 1982; Suppl. to Vol. 319:R31.

  254. Schrör K, Thomsen T. Kardioprotektive Wirkungen von Prostacyclin (PGI2) nach 2 und 4 Stunden bestehender Myokardischämie im Tierversuch. Z Kardiol 1981; 70:631.

Informationen für Probanden

Wenn Sie uns als Proband bei der Entwicklung neuer Medikamente unterstützen möchten, besuchen Sie bitte www.probandeninfo.de.